Zipalertinib
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Phase 3
Recruiting
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT05973773
- Locations
- 🇧🇷
ClÃnica Neoplasias Litoral, ItajaÃ, Santa Catatina, Brazil
🇹🇷Trakya Üniversitesi Sa?l?k Ara?t?rma ve Uygulama Merkezi, Edirne, Turkey
🇹🇷Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi, Etlik, Turkey
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Phase 2
Recruiting
- Conditions
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05967689
- Locations
- 🇮🇹
Azienda Unità Sanitaria Locale - Piacenza, Piacenza, Italy
🇪🇸Hospital Quirónsalud Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Fundación Jiménez DÃaz, Madrid, Spain
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Non Small Cell Lung CancerEGFR Exon 20 Mutation
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Cullinan Therapeutics Inc.
- Target Recruit Count
- 284
- Registration Number
- NCT04036682
- Locations
- 🇰🇷
Asan Medical Center (AMC), Soeul, Korea, Republic of
🇺🇸Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath